{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=177Lu-DOTATATE", "query": { "intervention": "177Lu-DOTATATE" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 47, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=177Lu-DOTATATE&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T20:01:38.303Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04543955", "title": "Telotristat With Lutathera in Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "Telotristat (Low-Dose)", "type": "DRUG" }, { "name": "Telotristat (High-Dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lowell Anthony, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1, "start_date": "2021-09-13", "completion_date": "2022-06-03", "has_results": true, "last_update_posted_date": "2023-06-27", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04543955" }, { "nct_id": "NCT05247905", "title": "Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Neuroendocrine Tumor", "Unresectable Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2023-02-16", "completion_date": "2033-10-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 171, "location_summary": "Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Emeryville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05247905" }, { "nct_id": "NCT03971461", "title": "Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Meningioma" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2019-05-15", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 2, "location_summary": "New York, New York • Cleveland, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03971461" }, { "nct_id": "NCT04711135", "title": "Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumors", "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "Lutetium [177Lu] oxodotreotide/dotatate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Accelerator Applications", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 11, "start_date": "2022-08-31", "completion_date": "2034-02-06", "has_results": true, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 3, "location_summary": "Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711135" }, { "nct_id": "NCT05249114", "title": "Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Lu-177", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-12-28", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05249114" }, { "nct_id": "NCT05109728", "title": "A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "[177Lu]Lu-DOTA-TATE", "type": "DRUG" }, { "name": "[68Ga]Ga-DOTA-TATE", "type": "DRUG" }, { "name": "Temozolomide", "type": "OTHER" }, { "name": "Radiotherapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 65, "start_date": "2022-05-10", "completion_date": "2027-05-24", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 4, "location_summary": "New York, New York • Pittsburgh, Pennsylvania • Houston, Texas + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05109728" }, { "nct_id": "NCT04609592", "title": "Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" }, { "name": "Gallium 68 Dotatate", "type": "DRUG" }, { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "PET/CT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-03-17", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04609592" }, { "nct_id": "NCT03923257", "title": "Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "177Lu-DOTA-tyr3-OCTREOTATE", "type": "DRUG" }, { "name": "Peptide Receptor Radiotherapy (PRRT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Sue O'Dorisio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Year to 20 Years" }, "enrollment_count": 0, "start_date": "2020-08-04", "completion_date": "2021-06-03", "has_results": false, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03923257" }, { "nct_id": "NCT05691465", "title": "Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation", "Metastatic Prostate Neuroendocrine Carcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68-DOTATATE", "type": "RADIATION" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 35, "start_date": "2023-12-27", "completion_date": "2026-11-02", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05691465" }, { "nct_id": "NCT05278208", "title": "Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Glioma", "Meningioma", "Embryonal Tumor", "Medulloblastoma", "Anaplastic Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "LUTATHERA® (Lutetium Lu 177 dotatate)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "4 Years to 39 Years" }, "enrollment_count": 65, "start_date": "2022-11-21", "completion_date": "2033-11", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-13T20:01:38.303Z", "location_count": 4, "location_summary": "Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05278208" } ] }